Geniposide ameliorates acute kidney injury via enhancing the phagocytic ability of macrophages towards neutrophil extracellular traps

Eur J Pharmacol. 2023 Oct 15:957:176018. doi: 10.1016/j.ejphar.2023.176018. Epub 2023 Aug 25.

Abstract

Acute kidney injury (AKI) is a clinically serious disorder associated with high mortality rates and an increased risk of progression to end-stage renal disease. As an essential supportive treatment for patients with respiratory failure, mechanical ventilation not only save many critically ill patients, but also affect glomerular filtration function by changing renal hemodynamics, neurohumoral and positive end-expiratory pressure, eventually leading to AKI. AMP-activated protein kinase (AMPK), a crucial energy homeostasis regulator, could enhance macrophage phagocytic ability and inhibit inflammation, but whether it can engulf neutrophil extracellular traps (NETs) and alleviate mechanical ventilation-associated AKI is still unclear. In this study, we found that geniposide significantly ameliorated histopathological damage, reduced serum Cre and BUN levels. Besides, geniposide can also induce AMPK activation and enhance macrophage phagocytic ability toward NETs. Moreover, geniposide can markedly reduce the levels of high mobility group box 1 (HMGB1), and these effects were dependent on AMPK-PI3K/Akt signaling. Altogether, these results indicated that geniposide promoted macrophage efferocytosis by inducing AMPK-PI3K/Akt signaling activation, clearing NETs and ameliorating AKI.

Keywords: AKI; AMPK-PI3K/Akt signaling; Efferocytosis; Geniposide; HMGB1; Mechanical ventilation; NETs.

MeSH terms

  • AMP-Activated Protein Kinases
  • Acute Kidney Injury* / drug therapy
  • Extracellular Traps*
  • Humans
  • Macrophages
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt

Substances

  • geniposide
  • AMP-Activated Protein Kinases
  • Phosphatidylinositol 3-Kinases
  • Proto-Oncogene Proteins c-akt